Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Session IV: Modulators of Immune Escape Mechanisms

Checkpoint blockade in tumor therapy: New insights and opportunities

James P. Allison
James P. Allison
Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Over the past several years it has become apparent that the effectiveness of active immunologic strategies for cancer therapy have been limited by cell intrinsic and extrinsic regulatory pathways that act in concert to shape the magnitude, quality, and location of immune responses in order to maximize target destruction and minimize harm to normal tissues. The prototype of cell intrinsic "checkpoints" whose blockade enhances anti-tumor responses is CTLA-4, which has been extensively studied in a large number of animal models and shown to be quite effective in achieving, either as a single agent or in combination with other agents, complete tumor eradication and long lasting tumor immunity. Over 3,500 patients have been treated with an antibody to human CTLA-4 (Ipilimumab, Medarex and Bristol-Meyers Squibb). Significant responses, including complete remissions, have been observed in about 15% of metastatic melanoma patients. This has led to considerable effort to identify biomarkers that would be useful in determining the impact of CTLA-4 on human immune responses in order to identify changes that might correlate with clinical responses, as well as to address combinatorial strategies that might enhance the effectiveness/frequency of clinical responses.

We have shown in melanoma and prostate cancer models in mice that tumor rejection is closely correlated with an increase in the ratio of both CD4 and CD8 effector cells to FoxP3+ regulatory cells. We have also found that CTLA-4 blockade decreases either the conversion of self reactive FOXP3- effector CD4 T cells to Foxp3+ Treg and/or the migration of converted cells into the tumor.

In a presurgical bladder cancer trial it has been shown that CTLA-4 results in an increase in the ratio of IFN-γ producing effector cells that express high levels of the CD28/CTLA-4 homolog ICOS. We have confirmed this in mouse models of melanoma and prostate cancer, and preliminary data suggest that an antibody to ICOS can enhance the therapeutic effects of anti-CTLA-4 in a melanoma model. We have also shown that intratumoral T cells express high levels of another coinhibitory molecule, PD-1, in which there has been considerable interest recently, and have found that blockade of PD-1 together with CTLA-4 enhances anti-tumor responses.

We have also examined two new combinatorial therapies involving CTLA-4 blockade: cryoablation and adoptive T cell transfer. In both we found significant synergy resulting in rejection of tumors that either treatment alone could not achieve.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by James P. Allison
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 2)
January 2008
Volume 8, Issue Suppl 2
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Checkpoint blockade in tumor therapy: New insights and opportunities
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Checkpoint blockade in tumor therapy: New insights and opportunities
James P. Allison
Cancer Immun January 1 2008 (8) (Suppl 2) 15;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Checkpoint blockade in tumor therapy: New insights and opportunities
James P. Allison
Cancer Immun January 1 2008 (8) (Suppl 2) 15;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PD-1, PD-L1 and their ligands: Regulating the balance between T cell activation and tolerance
  • Myeloid-derived suppressor cells in cancer
Show more Session IV: Modulators of Immune Escape Mechanisms
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement